Invitae closes $1.4B acquisition of Boulder’s ArcherDX
BOULDER and SAN FRANCISCO — Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold.
In a statement Monday, Invitae said it will pay $325 million in cash and up to 30 million shares to ArcherDX’s investors, along with 27 million additional shares linked to future milestones.
ArcherDX CEO Jason Myers will remain as the business head and will join Invitae’s board.
“With the addition of ArcherDX’s technologies, capabilities and team, Invitae is now well…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
A trio of Boulder startup scene veterans is reviving the local Techstars accelerator program, which…
-
TiFin Group , a Boulder-based financial technology umbrella company, has offloaded its ownership stake in…
-
Kuhl, a Salt Lake City-based outdoor-apparel brand, will open its first Colorado retail location in…
-
Boulder’s Human Relations Fund, which supports community-initiated activities that focus on civil rights, human rights…
